University of Texas – Austin

OnKure is working closely with Dr. Gail Eckhart’s laboratories at the University of Texas-Austin, Dell medical School. The collaboration is focused on translating our research into tools and treatments to improve patient health outcomes, with a focus on precision medicine that personalizes cancer treatments based on the latest developments in molecular diagnostics. Dr. Eckhardt’s translational research team is focused on identifying rational combinations of targeted therapies that include epigenetic primers with an emphasis on identifying useful biomarkers for patient stratification.

University of Colorado Boulder and Anschutz Medical Campuses

OnKure is working closely with several laboratories at the University of Colorado Boulder and Anschutz campuses towards understanding how epigenetic priming, particularly with HDAC inhibition, can impact the molecular mechanisms involved with cancer immune evasion with the goal of identifying novel drug combinations that can be applied to specific indications and patient populations. The Anschutz Medical Campus is also an OnKure Phase-1 clinical partner.

KDAc Therapeutics, Inc.

KDAc Therapeutics, Inc.

OnKure entered into an exclusive license and option agreement with Massachusetts-based KDAc Therapeutics, Inc. to support the continued development of KDAc’s HDAC3 selective inhibitor program. KDAc Therapeutics is a biotechnology company founded on technologies licensed from the Broad Institute of MIT and Harvard to translate discoveries in lysine acetylation and epigenetic regulation into novel treatments for cancer patients.